What is Peroxitech?
Operating at the intersection of biotechnology and respiratory medicine, Peroxitech focuses on the development of novel peptide therapeutics designed to mitigate the physiological damage associated with acute lung injury. By leveraging advanced molecular engineering, the company aims to address significant unmet medical needs in critical care settings. Its market position is defined by a commitment to high-barrier-to-entry pharmaceutical research, where the development of targeted, effective treatments for inflammatory lung conditions remains a primary objective for the firm's scientific leadership.
How much funding has Peroxitech raised?
Peroxitech has raised a total of $25M across 1 funding round:
Series A
$25M
Series A (2022): $25M with participation from Perceptive Xontogeny Venture Fund
Key Investors in Peroxitech
Perceptive Xontogeny Venture Fund
A specialized venture capital firm focused on providing early-stage and growth-stage financing to life sciences companies developing transformative medical technologies.
What's next for Peroxitech?
With the recent infusion of capital, Peroxitech is expected to accelerate its clinical trial roadmap and expand its internal research capabilities. The strategic allocation of these funds will likely prioritize the optimization of its lead peptide candidates and the strengthening of its intellectual property portfolio. As the company moves deeper into the enterprise-level scaling phase, stakeholders will be monitoring the progression of its clinical milestones, which are essential for validating the efficacy of its therapeutic platform in human subjects and securing future regulatory pathways.
See full Peroxitech company page
